SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and reports of heavy leveraged-position liquidations are driving the conversation, with traders debating whether the move marks capitulation or signals more downside. Some see a buying opportunity and expect a bounce, while others cite weak support and fear of further crypto-market losses.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is drawing attention after a sharp slide alongside Bitcoin and the broader crypto market, with traders pointing to market-wide selling rather than a confirmed XRP-specific catalyst. The break below a key psychological level has fueled fears of further losses, while other traders see an oversold dip and are accumulating.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,738,272,860.16806072. The last known price of Dogecoin is 0.06457313 USD and is down -2.71 over the last 24 hours. It is currently trading on 1545 active market(s) with $672,498,596.98 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoins sharp drop alongside a broader crypto selloff dominates the discussion, with traders worried about fresh multi-year lows and further losses. Others see the weakness as a buying opportunity, citing dip-buying and possible technical signs of a rebound.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,215,668.80579185. The last known price of Ethereum is 1,929.81008702 USD and is down -4.05 over the last 24 hours. It is currently trading on 14342 active market(s) with $15,325,408,368.61 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is caught in a broad crypto selloff, with traders citing Bitcoin weakness and forced liquidations alongside wider risk-off pressure and macro concerns. Sentiment is split between calls that the decline may be capitulation and expectations of further losses, while some traders are buying the dip.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,964,197.93006099. The last known price of Zcash is 932.62986485 USD and is down -2.50 over the last 24 hours. It is currently trading on 670 active market(s) with $1,142,095,783.67 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention for a steep, volatile pullback after a major rally, with traders linking the decline to broader crypto weakness, Bitcoins direction and liquidation pressure. The community is split between seeing broken support and further downside versus treating the drop as oversold accumulation; Zcashs privacy thesis and NU7 upgrade also feature in bullish arguments.

Quant (QNT) is a cryptocurrency and operates on the Ethereum platform. Quant has a current supply of 14,881,364 with 12,072,738 in circulation. The last known price of Quant is 159.21664083 USD and is down -1.76 over the last 24 hours. It is currently trading on 414 active market(s) with $110,625,382.40 traded over the last 24 hours. More information can be found at https://quant.network/.

Quant

Quant is drawing attention after a steep selloff alongside broader crypto weakness, with traders debating whether the pullback has further to run or is a buying opportunity. Many are accumulating on weakness based on the long-term tokenized-banking and Clearing House thesis, while skeptics question the tokens near-term demand before the network goes live.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,140,678.86417527 in circulation. The last known price of Hedera is 0.06118377 USD and is down -3.83 over the last 24 hours. It is currently trading on 468 active market(s) with $73,346,897.90 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBAR is drawing attention after traders linked its sharp rally to Nvidias involvement in the Hedera Council and Hederas presence in Nvidias Open Agent Safety Platform. The community is split between viewing the AI association as a meaningful catalyst and calling the move hype or a sell-the-news pump as the token pulls back.

Avalanche (AVAX) is a cryptocurrency launched in 2020. Avalanche has a current supply of 471,413,006.3506458 with 446,411,006.3506458 in circulation. The last known price of Avalanche is 8.22945358 USD and is down -1.18 over the last 24 hours. It is currently trading on 1135 active market(s) with $300,004,829.78 traded over the last 24 hours. More information can be found at https://avax.network/.

Avalanche

AVAX is drawing attention for a sharp selloff amid broader weakness in Bitcoin and altcoins, with traders saying it is falling harder than peers and giving back recent gains. The mood is largely bearish, though some holders are buying the dip and arguing the pullback may offer an accumulation opportunity.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,648,344.194204 with 36,816,370,531.313927 in circulation. The last known price of Cardano is 0.16792499 USD and is down -4.07 over the last 24 hours. It is currently trading on 1752 active market(s) with $304,416,326.91 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

ADAs steep decline amid broader crypto weakness is driving bearish talk of further losses and frustration with its prolonged underperformance. Traders are split between selling or waiting for lower levels and buying the dip for a rebound; some also cite Charles Hoskinsons comments that Cardanos roadmap is complete as a source of disappointment, while bullish squeeze calls remain speculative.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows earnings update and weaker outlook have fueled a sharp selloff, with traders pointing to rising mortgage rates and a sluggish housing market as headwinds. The community is split between bearish concerns about further downside and bulls viewing the decline as a buying opportunity.

statis crypto Watchlist

Solana

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the company will participate in the following investor conferences:Stephens Annual Investment Conference in Nashville, TNFireside chat on Tuesday, November 17, 2026...

NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of +16.67% and +0.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics Reports Third Quarter 2026 Results

NeoGenomics, Inc. (NASDAQ: NEO) (the Company), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third-quarter results for the period ended September 30, 2026. Financial Highlights For the three-month period ended September 30, 2026, as compared...

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

NeoGenomics, Inc. (NASDAQ: NEO), a provider of oncology diagnostic solutions that enable precision medicine across the cancer care continuum, has expanded its partnership with Indica Labs, a global leader in AI-powered digital pathology. The collaboration is intended to scale NeoGenomics' digital...

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026. Company management will...

What's Going On With NeoGenomics Stock Tuesday?

NeoGenomics stock falls after leadership shuffle and Q3 preliminary results. Analysts weigh in on growth and valuation.read more...

This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names.read more...

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

NeoGenomics, Inc. (NeoGenomics or the Company) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned succession, its Board of Directors has appointed Warren Stone, current President and Chief Operating Officer...

Why Women-Run Companies Deserve a Place in Your Portfolio

BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.

Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

• Reported GAAP EPS of $0.07 up 133.33% YoY
• Reported revenue of $209.25M up 11.42% YoY
• NeoGenomics raised full-year 2026 consolidated revenue guidance to $807M$809M and adjusted EBITDA guidance to approximately $60M; full-year net loss guidance is -$32M-$30M, with adjusted EBITDA approximately 38% above FY 2025.

NeoGenomics clinical volume increased 2% as average revenue per test reached $530; cash was $139.28M at September 30, and disclosed reimbursement, regulatory, and supply-cost risks.

NeoGenomics recorded 11% revenue growth, 29% NGS revenue growth, expanded gross margins, added a third Medicare-covered RaDaR ST indication, and expanded commercial payer agreements for new tests.

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Neogenomics Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>J.M. Smucker climbed to nearly a three-year high of $134.85 after the company posted better-than-expected fiscal 2027 first-quarter results.&nbsp;</li><li>JPMorgan kept an ‘Overweight’ rating on Replimune and raised its price target to $21 from $20.&nbsp;</li><li>NeoGenomics secured expanded Medicare coverage for its RaDaR ST liquid biopsy test.&nbsp;</li></ul><p>J.M. Smucker Co. (SJM), Replimune Group (REPL) and NeoGenomics (NEO) hit fresh 52-week highs on Wednesday, fueled by company-specific catalysts. Improving volumes at Smucker, clinical momentum at Replimune and Medicare coverage for NeoGenomics’ cancer test gave investors fresh reasons to buy.&nbsp;</p><p>J.M. Smucker and NeoGenomics stocks gained over 4% and 3%, while Replimune stock climbed 0.5%.&nbsp;</p><h2 class="st-heading-2">J.M.&nbsp;Smucker Gains On Improving Volumes</h2><p><a href="https://stocktwits.com/symbol/SJM">J.M. Smucker stock</a> reached nearly a three-year high of $134.85 after the packaged-food company delivered stronger-than-expected first-quarter fiscal 2027 results. The performance prompted BTIG to increase its price target to $150 from $130 while keeping a ‘Buy’ rating.</p><p>The key signal for investors was a recovery in underlying product volumes. With Hostess excluded, each of Smucker’s operating businesses posted volume gains during the quarter. The company’s Q2 revenue of $2.2 billion and earnings of $3.24 both exceeded analysts' consensus expectations of $2.1 billion and $2.2 per share, respectively, according to Fiscal Ai data.&nbsp;</p><p>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">Replimune Builds On Clinical Momentum</h2><p><a href="https://stocktwits.com/symbol/REPL">Replimune stock</a> climbed to an annual high of $15.99 as investors continued to respond to developments surrounding its cancer-treatment pipeline. JPMorgan raised its price target to $21 from $20 and maintained an ‘Overweight’ rating.</p><p>The firm pointed to support from key opinion leaders for the company’s approach to treating melanoma patients whose disease has stopped responding to PD-1 therapies. Replimune’s Tudriqev program has emerged as an important part of that opportunity as the company advances through major regulatory approvals.</p><p>Retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">NeoGenomics Gets A Reimbursement Boost</h2><p><a href="https://stocktwits.com/symbol/NEO">NeoGenomics stock</a> also reached a new 52-week high of $17.45. The company received a Medicare coverage determination for its RaDaR ST liquid biopsy test, which is designed to help detect minimal residual disease and assess treatment response.</p><p>Medicare reimbursement could make it easier for physicians to include the test in cancer care. The decision could expand NeoGenomics' commercial opportunity by reducing a major hurdle to wider adoption by oncology practices. However, retail sentiment around the stock remained in ‘bearish’ territory.</p><p>So far this year, SJM, REPL and NEO stocks have gained between 33% and 63%.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anf-stock-is-on-fire-after-strong-q2-why-jefferies-still-sees-18-more-upside/cZY8mnGRJpO">ANF Stock Is On Fire After ‘Strong Q2’ — Why Jefferies Still Sees 18% More Upside</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, a hand holds a smartphone displaying the logo of The J.M. Smucker Company.

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? 

Earnings, drug development, and healthcare reimbursement fueled the stock rallies.

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?

Equity

Earnings, drug development, and healthcare reimbursement fueled the stock rallies. 

Replimune Group Inc

J.M. Smucker Co.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

NEO Neogenomics Inc.

Fundamentals

Latest NEO News